What is a reason to pause?

Missing prescription or missing names

As of September 2026, federal law bars supplying prescription medicine without a valid prescription.

FDA (U.S. Food and Drug Administration) identifies this as a warning sign.

FDA says it has found false pharmacy names on compounded semaglutide and tirzepatide labels, as of September 2026.

• Get the pharmacy’s full name.
• Check it against the state board record.
• Find out how you can contact a clinician once the medicine has arrived.

A research label or an approval claim

In its September 2026 warning, FDA cautions against consumer products marketed for human use despite labels saying they are for research. Their quality is unknown, and using them could cause harm.

The September 2026 FDA position says it is false to describe a compounded medicine as having FDA approval.

• Ask whether the product is approved or compounded.
• Ask for the exact ingredient and product name.
• Do not let a research label substitute for a care explanation.

Pressure around price or payment

The FDA pharmacy checklist warns about prices that look too cheap to be real. Price by itself cannot show whether an offer is legitimate.

In a July 2026 alert, the FTC, the federal agency that protects consumers, warns about sellers who allow only certain ways to pay. These include bank or wire transfers, digital money called cryptocurrency, payment apps and gift cards. Such demands are a sign of a likely scam.

• Get the ongoing cost and cancellation terms.
• Check the names before entering payment details.
• Keep a copy of the written answers.